I could not resist another top up this morning. |
Bully boy Group thinking ................
welcome BullyGoy ..... |
what is actually said
Scancell could sell all
Scancell could partner
All the rest is just ""Puffed"" up pontification ...............
and the posts are worthless they are in RNS after all done in 2 lines |
I am just wondering whether our resident Trump fanboy has a birthday coming up. In which case, we could crowd fund one of these. |
 just read these two posts 4 hrs apart ...................
emptyend
Posted in: SCLP
Posts: 1,036
Price: 9.56
No Opinion
RE: Proactive Interview30 Jan 2025 10:20
Loading up is the right course, roses. Some of those complaining also say they have been selling today so, by rights (and assuming they are honest 😬) we should be hearing a lot less from them in future! 👍
I did the same on the dip last year, to slightly below the current levels. We now know that pivotal news on both main products is due in the middle of this year - so I continue not to rule out a bid for the whole company as that point approaches, especially if at least one of the GenMab deals seems likely to generate further milestone payments, as indicated in the results.
emptyend
Posted in: SCLP
Posts: 1,036
Price: 9.66
No Opinion
RE: Interims . . .30 Jan 2025 07:35
IMO these snippets (which I had also noted) are pointing towards partnering for the registration trial of iSCIB1+. Whilst I agree dilution is a risk, remember that a Board decision to dilute shareholders would potentially dilute everyone around the table - and is only likely to be taken if both Vulpes and Redmile stand their corner. partnering continues to be more likely though, I think, the board would have a clear bottom line on the terms of such an agreement and would potentially be prepared to go it alone.
Personally I think there will be a partnering deal announced in Q3. More straws in the wind from the analysts call, I suspect. |
Marking Time you are the Ultimate "smart Alec"
Now just consider who is the Smart Alec
‘smart Alec’ before - or at least some sort of variation. It’s not the nicest turn of phrase, usually meaning someone who is an obnoxiously conceited and self-assertive person with pretensions of smartness or cleverness. Essentially, they think they're more clever than they really are.
show us the evidence that you are actually Smart ??????
FFS ... this is the problem knowlesi of showing humility ...
how do you do this with Smart Alecs ... ??????
people that think they know more that Lindy Durrant
people that think they can Run PLC's Better
MT ....
what do "YOU" actually contribute ................
F#ck all ! |
Ha !
please put one one post of yours of Value ? Marking Time
seriously !!
have you ever delivered a nugget ?
its impossible to put this much detail about scancells science in one or two posts
it would run to pages .. |
Perhaps Inane is trying to stay ahead of the frequency of earthquakes in Santorini?Whatever the reason, its like being next to the nutter of the bus who literally can't stop jabbering. I'm sure there must be a nugget in there somewhere, but really can't be bothered to sift through the excrement.Sometime less is more, Inane. Try cutting your posting rate to twice a week and actually thinking about what you say |
I feel like i am Rucks Shrink ....
I should get paid for this ! |
so stop trying to deliver "smart alec" posts ...its never worked for you
because you try to do it as a "trip up" |
Yes its the going rate for a small number of shares Ruck
but can you buy 600m of them taking you past 50% |
Scancell have already told you, i will let you research that Eh !
its called "contribute"
rather than "obfuscate"
many play this game
which one has failed ???
""to avoid answering a difficult question means you are committing the Obfuscation Fallacy.""" |
"how is your ?199 buy going"A lot less down than you recent buys |
"so this is your problem Ruck"I don't have a problem. I understand that if I want to raise cash today I would get 9.25p per share, that is the "going rate". |
then i will leave you with "if Only" Ruck
how is your £199 buy going .... "if only" |
Inan,What's the plan, if any, for a trial in ovarian cancer? |
which leaves "what if and if only"
is it chlorinated Chicken ?
Factory laid eggs with salmonella
Diversity of the chicken
mixed race chicken
transgender chicken ...
many reason why it may not be edible ...
however you do drink Chlorinated water and swim in it |
"show the mechanism of failure"9.25p says it all doesn't it? |
but I suppose a TuT from Bermuda ...is all we can expect
' |
Now
I would be so impressed if ....
Bermuda
Burble
Marking Time
Torquay Fan
MIa
Marcus
SC102
Ivy
Wildforce
Knowlesi
Ruck
the list goes on and on
"show the mechanism of failure" of the science
and I would point out raising Money has not Failed Scancell yet and most funding failures is because of Poor Results in the science
you can be as commercially focused as you like ... but without product efficacy that's a tough call
and why is scancell so commercial
its the difference between standard of care and the Efficacy of the combination
the risk dissipates |
seems that many ..............
Have the chicken and the Egg
but have not yet worked out they are edible . |
so if Scancell Moditope HAS control in Ovarian
it "WILL" synergise with balstilimab and zalifrelimab
Not maybe .....
otherwise answer the question
which one has failed to show a response !! |
Now if you think that Bristol Myers Do not know that ... you really are in the wrong game ....
an "untouched market" in ovarian cancer for checkpoints
Conclusion
Promising and durable clinical activity, with favorable tolerability, was seen in this largest trial to date evaluating dual programmed death-1/cytotoxic T-lymphocyte–associated antigen-4 blockade in patients with recurrent and/or metastatic cervical cancer. Further investigation of the balstilimab and zalifrelimab combination in this setting is continuing.
The median follow-up was 21 months. The confirmed ORR was 25.6% (95% CI, 18.8 to 33.9), including 10 complete responders and 22 partial responders, with median duration of response not reached (86.5%, 75.5%, and 64.2% at 6, 9, and 12 months, respectively). The ORRs were 32.8% and 9.1% in patients with programmed death ligand-1–positive and programmed death ligand-1–negative tumors, respectively. For patients with squamous cell carcinoma, the ORR was 32.6%. The overall disease control rate was 52% (95% CI, 43.3 to 60.6). Hypothyroidism (14.2%) and hyperthyroidism (7.1%) were the most common immune-mediated adverse events. |
what i can tell you .....
Moditope induced inflammation in the Ovarian cancers sufficient to stabilise them
but
That upregulates the Pd-1 on the cancer ...
It up-regulates T regs
etc etc
that cancer is fighting back ...
bring in the checkpoints !!
"none approved"
which means YOU pay for them not the NHS |
your response should have been Ovarian ""has Not been dropped""
Ruck posted
"One cancer target has been dropped"
this is Wrong
AI Overview
Learn more
As of today, there are currently no approved immune checkpoint inhibitors specifically for ovarian cancer, meaning that no checkpoint-based immunotherapy is considered a standard treatment option for this type of cancer; clinical trials have shown limited efficacy for these drugs in ovarian cancer patients. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
